• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CluePoints launches data quality oversight service for site inspection readiness

CluePoints launches data quality oversight service for site inspection readiness

November 2, 2016
CenterWatch Staff

CluePoints, a provider of Risk-Based Monitoring (RBM) and Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced a new Data Quality Oversight service, RADAR, aimed at helping sponsors achieve a data-driven understanding of risks to an inspection-ready level. As regulators insist that sponsors adopt more comprehensive quality oversight methodologies, this new service looks to move away from antiquated processes to a more rigorous statistical approach to operational quality assurance including preparation for site inspections.

CluePoints’ RADAR service harnesses the advanced statistical interrogation of clinical and operational study data to identify investigative sites with a preponderance of anomalous, missing or inconsistent data that may require inspection readiness action. The company’s Data Analysts conduct a comprehensive assessment using the software to identify these higher-risk sites and data which may have escaped detection previously. This rigorous approach is anticipated to benefit sponsor submissions by identifying anomalous sites along with the nature and extent of potential data issues.

“The launch of our ground-breaking RADAR service marks another exciting development in data quality-driven risk analysis. This unsupervised, independent solution will help clinical research organizations to move away from existing time-consuming, approximate and costly procedures,” said Franҫois Torche, CEO, CluePoints. “It analyzes data trends over time to help comply with regulators’ standards, ensuring data quality and ultimately mitigating risks and improving the safety of patients.”

Inspiring confidence throughout the process, this service is an extremely cost-effective alternative to traditional site inspection readiness planning. It provides a report that ranks the most anomalous sites, identifies areas of risk across site and patient data and anticipates where regulators might also target their site inspections. Companies are adopting the RADAR service to use across Clinical Operations, and now in particular for Clinical Quality, Auditing and Inspection Readiness. Sponsors can access all these benefits through CluePoints’ outsourced service approach, and alternatively can obtain the CluePoints’ platform for internal, enterprise level adoption.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing